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Introduction: The regulatory T cells (Treg) are thymus-derived suppressor 
cells which play a critical role in maintaining immunological tolerance to self-
antigens. Here, I describe a new approach to generating potent specific Tregs, 
using a chimeric antigen receptor (CAR) targeting CD40L. CARs are fusion 
proteins composed of an extracellular portion that is usually derived from 
antibodies and intracellular signaling portion derived from T cell signaling 
proteins. I generated a recombinant gene encoding a full length of the 
cytoplasmic domain of CD28, IL-2Rβ, TGF-βR1, and CD3ζ fused with a scFv 
of the MR1 mAb specific to CD40L as extracellular domain. Functionality of 
the cloned CAR was confirmed in EL4 cells by stimulation with HEK293 cells 
expressing CD40L. 
 
Methods: Mouse CD4+ T cell was isolated by magnetic-activated cell sorting 
(MACS) separation system according to the manufacturer’s instructions. And 
this gene was used to compose the CAR construct. Each gene was obtained and 
extended using specific oligonucleotides by PCR. The synthesized CAR 
construct was inserted into a lentiviral expression vector. Using this vector and 
packaging vectors, the CAR was transfected and resulted in the production of 
lentivirus. The harvested virus was transduced in EL4 cell.   
 
Results: The CAR construct was obtained and elongated from mouse cDNA. 
And, synthesized CAR constructs cloned into a lentiviral expression vector. The 
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expression of CAR was confirmed by ZsGreen1 fluorescence in pLVX-IRES-
ZsGreen1 vector. Also, the cell line expressing CD40L of antigen to CAR was 
generated and confirmed by fluorescence of mCherry. The co-culture of EL4 
cell expressing CAR on the response of HEK293FT cell expressing CD40L was 
conducted. The activation of EL4 cells was examined by CD69 expression level. 
 
Conclusions: I describe a unique strategy to generate CAR. This novel CAR 
retains an identical costimulatory and CD3ζ signaling regions but also include 
an intracellular domain of IL-2R β  and TGF- β R1. The inclusion of the 
intracellular domain of IL2-Rβ and TGF-βR1 enabled conversion of naïve T 
cells to iTreg in an antigen-dependent manner. Therefore, I expect this CAR 
construct would generate significant suppression effect in transplantation or 
autoimmune disease model. This CAR with CD40L specificity might provide 
a novel strategy to achieve tolerance in various immunopathologic conditions. 
 
------------------------------------- 
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The Tregs are thymus-derived suppressor cells and a subpopulation of T cells 
that modulate the immune system, maintain tolerance to self-antigens and 
prevent autoimmune disease. Tregs can be defined as a T cell population that 
functionally suppresses an immune response by influencing the activity of 
another cell type. So far, many studies have been done using Treg. Among them, 
the adoptive transfer is one of the methods for the treatment as cell therapy (1). 
Here, I describe what I believe is a new approach to generating potent specific 
Tregs, using a CAR targeting CD40L. I discussed here the generation and 
signaling properties of CARs, focusing on their conversion on T cell specificity 
and potency.  
CARs are fusion proteins composed of an extracellular portion that is usually 
derived from antibodies and intracellular signaling portion derived from T cell 
signaling proteins (2). The feature of CAR is their ability to bind specific 
antigen with MHC independent manner and capable of directing the specificity 
of T cells toward desired antigens. I aimed to generate a new CAR-iTreg 
specific for CD40L. The structure of CAR molecule includes an scFv, a spacer, 
transmembrane domain, and an intracellular signaling domain. I generated 
lentiviral vector encoding a CAR specific for CD40L by cloning the scFv of 
the MR1 mAb and fusing the portions of CD28, IL-2Rβ, TGF-βR1, CD3ζ in a 
second generation CAR structure (Fig 1 A).  
CAR-T cells are classified into three generations according to the existence of 
the costimulatory domain in the intracellular domain (3). The first generation 
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of CAR-T cells only has a single structure of CD3ζ in the intracellular domain. 
The CAR-T cells with CD3ζ were able to transmit signal like TCR into the cell. 
This first generation CAR-T cells were effective at killing tumor cells. But, 
these CAR-T cells did not get enough results because of insufficient 
proliferation, a short life span, and low expression of cytokine. Second 
generation CAR-T cells include the costimulatory molecule in the intracellular 
domain. CD28 is an essential mediator of T cells in the regulation of 
proliferation and survival (4). The second generation CAR-T cells transmit the 
costimulatory signal, such as CD28, 4-1BB or OX40, which can enhance the 
proliferation, cytotoxicity, life span of CAR-T cells. These CAR-T cells were 
conferred greater strength of signaling and persistence to the T cells, resulting 
in their overall higher potency. Third generation CAR-T cells have two 
costimulatory domain with CD3 ζ  in the intracellular domain. This CAR 
structure has improved proliferation and survival rate, but the killing ability was 
not improved compared to the second generation. So I synthesized the CAR 
based on second-generation design.  
CAR-T cell is a promising and novel therapy for a variety of cancer models 
(5). This CAR-T cells with specificity to CD19 have proved the effective 
function of killing tumor cell as well as 70~90% complete response (6). So, 
CAR-T cell therapies were also studied for the treatment of a solid tumor. These 
CAR-T cell therapies have therapeutic potential, efficiency, and specificity (7). 
This therapy using CAR was being studied not only in the cancer model but 
also in autoimmune diseases. In autoimmune diseases that require 
immunosuppressive function, the use of CAR construct has been developed 
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using Treg. The CAR-Treg has been studied in colitis, which targets TNP, and 
in multiple sclerosis, which targets myelin-oligodendrocyte glycoprotein 
(MOG) (8). Unlike in autoimmune diseases, however, the study has yet to be 
done on the transplantation model.  
It is a new and possible strategy to redirect the CAR with antigen specificity 
and applied it to the transplantation model. Tregs are immunosuppressive T cell 
with an important role in the maintenance of tolerance (9). In transplantation 
model, where the immune response takes place, Tregs that develop in the 
response of antigen presented by APC expand and proliferate. At first, the 
polyclonal Treg were used to suppress the immune response. Polyclonal Treg 
cells can suppress effector T cells with various specificity, but it is not enough 
to suppress the reject response after transplantation of graft because of the lack 
of donor antigen-specific Treg (10). So, Tregs have evolved with specificity to 
donor antigen by donor APC. Alloantigen-specific Tregs are more effective 
than polyclonal Tregs. But, as a therapy, there were limits to need for donor 
APC and long expansion time. So, next step, the CAR-Treg have been 
engineered with antigen specificity, applied to the transplanted mouse, and 
accepted graft in vivo (11). 
 Graft-specific CAR-Tregs changing nTregs via the transfer of CAR designed 
to recognize the MHC class allele A*02 was generated (12). These A2-CAR 
Tregs exhibited higher proliferative capacity, stable phenotype, and 
suppressing function than nTregs. Also, HLA-A2 specific CARs were 
engineered. These redirected CAR-Treg toward MHC-class I molecule 
represented superior to protect the graft from allograft rejection in vitro and a 
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human skin xenograft transplant model (13). These results demonstrated the 
possibility of CAR technology for clinical trials and new potential therapy. 
Thus, the CAR-Treg has an exceptionally positive result as a therapy, but there 
is a limit of separating the T reg and transducing the CAR. So, I designed that 
the naïve T cell could be conversed into Tregs by antigen stimulation, using 
CAR technology for more powerful suppressive function and proliferative 
capacity.   
Naïve CD4+CD25-T cells could be conversed into Tregs by co-stimulation 
with T cell receptors (TCRs) and transforming growth factor-β (TGF-β) (14). 
To induce TGF-β activation in CAR T cells in an antigen-dependent manner, 
I include a full length of the cytoplasmic domain of the TGF-β receptor in the 
intracellular domain. TGF-β receptors have three types, among them, TGF-
βR3 involved in capturing antigen, TGF-βR2 forms a complex with TGF-βR1 
and then activated TGF-βR1 phosphorylates SMAD2 (15). It is a critical role 
in the induction of TGF-β signaling is TGF-βR1-mediated. TGF-β and IL-6 
induce naïve T cells to become a Th17 cell. Moreover, IL-6 can convert Treg 
to Th17 cells. IL-2 and TGF-β stimulation lower IL-6 receptor expression and 
IL-6 signaling, resulting in the blocking of Tregs to Th17 conversion (16). So I 
included a full length of the signaling domain of the IL-2 receptor in the 
intracellular domain next to TGF-β receptor. IL-2 receptors have three types, 
among them, IL-2Rα involved in increasing the antigen binding affinity, IL-
2Rβ and IL-2Rγ formed dimerization and induce signal transduction (17). 
Primarily, IL-2R β  provide the docking site of JAK and results in 
phosphorylation of STAT5. 
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 During the generation of the immune response, several molecular signals are 
needed. A first signal is the engagement of the antigen receptor to antigen by T 
cell and APC. The second signal is the binding of costimulatory molecule 
expressed by T cell and APC with their ligands. CD40 bind CD40L, which is 
expressed on activated T cell results in modulating immune responses (18). So, 
the block of CD40/CD40L engagement might play an essential role in 
transplantation condition. Anti-CD40L co-stimulation blockade treated mice 
accepted a second graft without graft loss (19). It shows a possibility to study 
the mechanism of tolerance and new replacing therapy. But, there are limit anti-
CD40L blockade induces platelet activation and thrombosis results in critical 
issue in transplantation condition as well as an autoimmune disease model (20). 
Then, the research exhibited that an anti-CD40L blockade lacking Fc domain 
prevent thrombosis with successful immune suppressive function (21). Also, 
glycosylated anti-CD40L blockade still has a useful effect of preventing graft 
loss after transplantation (22). Therefore, the use of anti-CD40L support useful 
target therapy for transplantation and autoimmune disease. So, I determined the 




MATERIALS AND METHODS 
1. Isolation of Mouse CD4+ T cell 
Splenic CD4+T cell was isolated from mice by MACS magnetic separation 
system according to the manufacturer’s instructions (Miltenyi Biotec, Bergisch 
Gladbach, Germany). Briefly, spleen cell suspensions were incubated in cold 
PBS buffer with biotin-antibody cocktail/anti-biotin microbeads according to 
the manufacturer’s instructions (CD4+ T cell isolation kit, Miltenyi Biotec). The 
LS columns were placed in the magnetic field of MACS separator and rinsed. 
The suspension cell was loaded onto the LS columns result in CD4+ T cell were 
collected. 
 
2. PCR/Over-Extension PCR (OE-PCR) 
The OE-PCR consists of two DNA of interest and two oligonucleotide primer, 
which generate single-stranded DNA that is annealed together and extended 
under appropriate condition. The OE-PCR-based synthesis of the gene involved 
two rounds of PCR. The first rounds are to extend the gene fragment (Cd3ζ, 
Cd28 ) of approximately 20 bp corresponding to be connected to the next. Two 
pairs of an overlapping fragment from the first round were extended the one 
fragment in the second rounds PCR using the corresponding two-end primer of 
the connected gene. The PCRs were conducted as follows: a 5 min initial 
denaturation at 95°C; 35 cycles of 94°C for 30 s, annealing step (depends on 





The oligonucleotide was purchased from COSMO-genetech (Seoul, Korea) and 
mBiotech (Gyeonggi-do, Korea). The oligonucleotides were diluted to 10 mM 
with 3 distilled water (DW) before use. 
 
4. Cell line 
Both HEK293FT and EL4 cell line are obtained from American Type Culture 
Collection (ATCC, Manassas, VA). These cells were grown in DMEM-based 
media (Life Technologies, Carlsbad, CA). The culture media were 
supplemented with 10% heat-inactivated FBS, MEM-NEAA, HEPES, 2-
Mercaptoethanol, gluta-MAX (Life Technologies). All cells were grown at 
37°C in the presence of 5% CO2.  
 
5. Gel Electrophoresis/Sequencing 
Separation of DNA in 1% (±0.5) agarose gel were run at 100 V for 20 m in 
TAE buffer. The gel was exposed to UV light and the picture taken with a gel 
documentation system. Premix with Taq polymerase (Bioneer, Chungcheong-
do, Korea) and premix with Pfu polymerase (Mgmed, Seoul, Korea) were used 
during PCR. The 10 μl of the amplificated PCR product were loaded to each 
lane. The 4 μl of Gel marker from COSMO gentech were loaded each lane. The 
synthesized gene fragments were obtained by 1% (±0.5) agarose gel using 
electrophoresis and were purified by PCR purification kit (COSMO-genetech) 
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or Gel extraction kit (COSMO-genetech). The elution was performed with 40 
μl. The DNA sequences were analyzed by COSMO-genetech. 
 
6. Transfection 
HEK293FT cells were co-transfected with plVX-IRES-ZsGreen1 (TAKARA 
Bio, Seoul. Korea) with CAR, pLP1 (Invitrogen, Carlsbad, CA), pLP2 
(Invitrogen), PLP/VSVG (Invitrogen) pDNA at a mass ratio of 1:1:1:1 using 
fugene HD transfection reagent. pDNA was prepared by Mini prep (Qiagen, 
Hilden, Germany), according to the manufacturer’s instructions. A total of 15 
μg of pDNA was added to 5×106 HEK293FT cells in 8 ml Opti-MEM media 
(Life Technologies). The media was changed at 24 h post-transfection. Viral 
supernatant was harvested 72 h post-transfection. 
 
7. Transduction of T cells 
The retrovirus with CAR-expressing pDNA was used for the infection of the 
EL4 cell line for 48 h. The transduction was performed on days 2 following the 
stimulation with anti-CD3/CD28 (eBioscience Inc, San Diego, CA) at a 
concentration of 5 μg/ml. And the expression was checked on day 4 or 5.  
 
8. FACS 
HEK293FT cell and EL4 cell were washed twice for 5 min in 1 ml FACS buffer 
at 500 x G. At the end of the washing step, the pellet was resuspended in 200 
μ l FACS buffer and analyzed using a FACS Canto flow cytometer (BD 
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Generation of the intracellular domain of the CAR 
The full length of mouse Cd28 sequence except for stop codon was PCR cloned 
with 5’ oligonucleotide forward primer CD28F (including Spe I site) and 3’ 
oligonucleotide reverse primer CD28R (including Spe I site), consisting of 
nucleotide 97-750 (Fig 1 B and 2 A, Table 1). The cytoplasmic sequence for 
CAR contains nucleotide 954-1766 of mouse Il2r𝛽. This gene was PCR cloned 
with 5’ oligonucleotide forward primer IL2RβΒF (including a Spe I site) and 3’ 
oligonucleotide reverse primer IL2RβR (including an Hinc II site). The stop 
codon of Il2r 𝛽  gene was eliminated (Fig 1 B and 2 B, Table 1). The 
cytoplasmic sequence for CAR contains nucleotide 532-1599 of mouse Tgf𝛽r1 
excepting stop codon. This gene was PCR cloned with 5’ oligonucleotide 
forward primer TGFβR1F (including a Spe I site) and 3’ oligonucleotide 
reverse primer TGFβR1R (including an Hinc II site) (Fig 1 B and 2 C, Table 
1). The signaling domain of cytoplasmic sequence for CAR contains nucleotide 
302-643 of mouse Cd3ζ. This gene was PCR cloned with 5’ oligonucleotide 
forward primer CD3ζF (including an Hinc II site) and 3’ oligonucleotide 
reverse primer CD3ζR (including a Not I site) (Fig 1 B and 2 D, Table 1). This 
PCR reaction produced single bands, which matched the expected size. Each 
primer sequence with specific restriction endonuclease site is incorporated into 
the PCR product during amplification. The single bands were obtained and 






Figure 1. Schematic diagram describing the component of the CAR genes.  
A) Scheme of CAR containing scFvs, CD28 hinge region, CD28 
transmembrane domain, CD28 costimulatory domain, IL2R β  intracellular 
domain, TGFβR1 intracellular domain, and CD3ζ.  






Figure 2. Acquisition of cytoplasmic gene. 
A PCR fragment from mouse cDNA was amplified by different annealing 
temperature as summarized in Table 1. Lane 3 was extracted. A) A CD28 PCR 
fragment of 666 bp from mouse cDNA. B) A IL2R𝛽 PCR fragment of 825 bp 
from mouse cDNA. C) A TGFR𝛽R1 PCR fragment of 1080 bp from mouse 



















































Table 1. The PCR conditions for acquisition of the cytoplasmic domain of 
CAR. 
The PCR product was amplified with specific restriction enzyme site using 













To induce conversion of CAR-T cell to inducible CAR-regulatory T cells 
(CAR-iTreg) in an antigen-dependent manner, I incorporated a full length of 
the cytoplasmic domain of Il2r𝛽 and Tgf𝛽r1 between the cytoplasmic domain 
of Cd28 and Cd3ζ . To generate synthesized construct of the cytoplasmic 
domain, I elongated Cd3ζ and Cd28 pDNA using CD3ζ(oe)F/CD3ζR and 
CD28F/CD28(oe)R respectively (Fig 3 A and B, Table 1 and 2). This particular 
primer contains about 20 bp of the overlapping end to be connected and results 
in the generation of 5’ or 3’ overhang on PCR product that is complementary 
to sequences at the end of each gene to be connected (Table 2). So, Cd3ζ gene 
was extended by including Tgf𝛽 r1 gene at 5’ ends. And Cd28 gene was 
extended by including Il2r𝛽 gene at 3’ ends. The OE-PCR using ‘CD28F and 
IL2RβR primers’ and ‘extended Cd28 gene fragment and Il2r𝛽 gene fragment’ 
as the template generated correct PCR product with expected DNA length. 
Likewise, The OE-PCR using ‘TGFβR1F and CD3ζR primers’ and ‘Tgf𝛽r1 
gene fragment and extended Cd3ζ gene fragment’ as the template generated 
correct PCR product with expected DNA length (Fig 3 C, Table 1). This PCR 




Figure 3. Elongation and synthesis of the gene for the cytoplasmic domain 
of CAR. 
A) The elongated PCR product using CD28F/CD28(oe)R primer sets. The PCR 
product of Fig2 A was used as a template. B) The elongated PCR product using 
CD3ζ(oe)F/CD3ζR primer sets. The PCR product of Fig2 D gene was used as 
a template. C) The result of OE-PCR. Lane 1 and 2 represent a ‘Cd28+Il2r𝛽’ 
and ‘Tgf𝛽r1+Cd3ζ’ gene fragment, respectively. The PCR product with the 











Table 2. The unique oligonucleotide sequences for OE-PCR. 
 
The CD28(oe)R primer containing 18 bp of 5’ IL-2Rβ gene synthesized the 
templates containing 3’ overhang of IL-2Rβ. The CD3ζ(oe)F primer containg 


















Each pDNAs could cleaved with appropriate restriction endonuclease (Spe I). 
The cleavage reaction resulted in the formation of the linearized part of pDNA 
with the restriction endonuclease site at the end of this fragment. The T vector, 
including Cd28+Il2r𝛽 gene was separated two strands as insert and T vector 
with Spe I restriction enzyme site at the end of strands. And the T vector, 
including Tgf𝛽 r1+Cd3ζ  gene was cut and produced long linear sequence 
including Tgf𝛽r1+Cd3ζ gene on T vector with Spe I restriction endonuclease 
site (Fig 4 A). The product of restriction endonuclease digestion, ‘Cd28+Il2r𝛽’ 
fragment to be cloned into the sticky end of ‘Tgf𝛽r1+Cd3ζ’ containing T vector 
by T4 ligase, and transformed into competent E coli. The transformation 
products were screened using a plate with antibiotics for selection. The colonies 
were identified by PCR at the expected DNA size using universal M13F/M13R 
primers (Fig 4 B). Among the checked transformed product, the second PCR 
was performed using M13R/CD28R primers for checking the correct 












Figure 4. Generation of the signaling domain of CAR. 
A) Separation of the Spe I digested pDNA. Lane 1 represents separated two 
strands (T vector, Cd28+Il2r𝛽  from the top side). Lane 2 and 3 represent 
linearized T vector including ‘Tgf𝛽r1+Cd3ζ’ gene. The fragment estimated 
gene size 1473 bp (Cd28+Il2r𝛽) and 5178 bp (Tgf𝛽r1+Cd3ζ) were extracted 
and purified. B) Screening of colonies for the presence of insertion. The PCR 
was implemented using M13R/M13F primer sets. The PCR fragment with 3075 
bp was confirmed and extracted. The lane 1,2,5 and 7 represent a correct band 
size. C) Confirmation of the insert orientation. The PCR was conducted with 
M13R/CD28R primer sets. The PCR fragment with 744 bp length was 








Generation of the extracellular domain of the CAR. 
The extracellular domain of CAR consists of the leader sequence, V region of 
the H chain of linked a (G4S)3 linker to the V region of L chain of the MR1 Ab 
(23). DNA for single-chain fragment variable (scFv) was obtained from MR1 
hybridoma to target CD40L (24). I synthesized VH-F and VH-R primer, which 
contained the part of leader sequence and 5’ end of the VH gene, and the 3’ end 
of the VH gene, respectively (Table 4). I amplified the VH gene using VH -F/ VH-
R sets from genomic DNA of MR1 cell line (Fig 6 A, Table 3). Likewise, I 
synthesized VL-F and VL-R primer, which contained the part of leader sequence 
and 5’ end of the VL gene, and the 3’ end of the VL gene respectively (Table 4). 
I amplified the VL gene using VL-F/ VL-R sets from genomic DNA of MR1 cell 










Figure 5. Schematic diagram presenting the extracellular domain of the 
CAR. 













Figure 6. Acquisition of the scFv gene. 
A PCR fragment from cDNA of MR1 hybrydoma was amplified by different 
annealing temperature as summarized in Table 3. Lane 2 was extracted. A) A 


















































Table 4. The oligonucleotide sequences for the acquisition of scFv. 
The VH-F primer and VL-F containing of 11 bp of 5’ leader sequence  

















The 30 nucleotides of linker sequence are synthesized as the part of VH-linker-
R primers and are added to the 3’ end of the VH gene during PCR with VH-F 
primer using VH gene as a template (Fig 7 A, Table 5 and 6). And, 33 
nucleotides of linker sequence are synthesized as the part of VL-linker-F 
primers and are added to the 5’ end of the VL gene during PCR with VL-R primer 
using VL gene as a template (Fig 7 B, Table 5 and 6). This special primer has 
repeated nucleotide encoding ‘G4S’ amino acid sequences. So, the PCR product 
results in the extended DNA sequence for the linker sequences. The signal 
peptide of the CAR consists of nucleotide 1-81 of mouse CD8 alpha chain (25). 
Using SP3/ VH-linker-R primers set, SP2/VH-linker-R primers set and VH-linker 
gene as a template, the signal peptide sequence was extended by PCR in 
sequential (Fig 7 C and D, Table 5 and 6). Using these special oligonucleotide, 








Figure 7. Elongation and synthesis of the gene for the extracellular domain 
of CAR. 
The result of gradient PCR with different annealing temperature as summarized 
in Table 5. A) The elongated PCR product using VH-F/VH-Linker-R primer sets 
and PCR product of Fig6 A gene as a template. B) The elongated PCR product 
using VL-Linker-F/VL-R primer sets and PCR product of Fig6 B gene as a 
template. C) The elongated PCR product using SP3/VH-Linker-R primer sets 
and PCR Product of Fig7 A gene as a template. D) The elongated PCR product 























































Table 6. The unique oligonucleotide sequences for extension of the scFv 
gene fragment. 
The VH-Linker-R primer containing of 30 bp of 5’ linker sequence  
synthesized the template containing 3’ overhang of linker sequence. The VL-
Linker-R primer containing of 33 bp of 3’ linker sequence synthesized the 
template containing 5’ overhang of linker sequence. The SP3 primer is 
complementary to 18 bp of 5’ VH and 33 bp of 3’ signal peptide genes. The SP2 
primer is complementary to 18 bp of 5’ SP3 and 15 bp of middle part of signal 
peptide genes. The SP1 primer is complementary to 17 bp of 5’ SP2 and 18 bp 
of middle part of signal peptide genes. The K1 primer is complementary to 19 
bp of 5’ SP1 and 20 bp 5’ signal peptide genes with restriction endonuclease 






The OE-PCR using SP2/VL-R-Sal I primers set and ‘SP2+VH+Linker gene and 
Linker+VL gene’ as the template generated correct PCR product with expected 
DNA length (Fig 8 A, Table 6, 7 and 9). The VL-R- Sal I primer has specific 
restriction enzyme site result in PCR product with Sal I sequence at the 3’ end 
during amplification by PCR. The PCR product was extended using SP1/VL-R-
Sal I primer set and then K1/VL-R-Sal I set by PCR in sequential (Fig 8 B and 
C. Table 6, 7 and 9). These PCR products were extracted and cloned to the T 
vector. The transformation products were screened using a plate with antibiotics 















Figure 8. Generation of the extracellular domain of CAR. 
The result of PCR with different annealing temperature as summarized in Table 
7. A) The result of OE-PCR. The PCR was implemented using SP2/VL-R-Sal I 
primer sets and PCR product of Fig7 B/Fig7 D gene as a template. B) The 
elongated PCR product using SP1/VL-R-Sal I primer sets and PCR product of 
Fig8 A gene as a template. C) The elongated PCR product using K1/VL-R-Sal 






























































Synthesis of CAR structure. 
The extracellular spacer region consists of residues 340-450 of mouse Cd28 
region (26). The intracellular domain of CAR with spacer region was generated 
using Hinge-CD28-Sal I/CD3ζ-Not I primer sets by PCR with pfu polymerase 
(Fig 9 A, Table 8 and 9). These PCR products were extracted and cloned to the 
T vector. The transformation products were screened using a plate with 
antibiotics for selection. The size of the insertions in the transformants using 
M13F/M13R primers sets has been confirmed by PCR. The pDNA of scFv and 
Ecto/cytoplasmic domain gene can be cleaved with appropriate restriction 
endonucleases (Sal I and Not I) (Fig 9 B). The cleavage reaction results in the 
formation of the linearized part of pDNA with the restriction endonuclease site 
at the end of this fragment, respectively. This product was cloned into the sticky 
end of ‘scFv’ vector by T4 ligase and transformed. The transformation products 
were screened using a plate with antibiotics for selection. The colonies were 













Figure 9 Generation of CAR on the T vector.  
A) The PCR was implemented using Hinge-CD28-Sal I/CD3ζR primer sets and 
PCR product of Fig4 C gene as a template with different annealing temperature 
as summarized in Table 8. B) Separation of Sal I and Not I digested pDNA. 
Lane 1 represents linearized T vector including scFv gene. Lane 2 represent 
separated two strands (T vector, ecto/cytoplasmic domain from the top side). 
The fragment estimated gene size 4654 bp (scFv+T vector) and 2550 bp 





















































Hinge-CD28-Sal I  GTCGAC AAAATTGAGTTCATGTAC 
VL-R-Sal I GTCGAC TTTTATCTCCAGCTTGGTGC 
 
Table 9. The unique oligonucleotide sequences for production of gene 
fragment. 






















Transfer of CAR structure to a lentiviral expression vector. 
I attempted inserting the CAR DNA construct into pLVX-IRES-zsGreen1 
vectors. With such a long sequence of the CAR, it was challenging to generate 
lentiviral expression vector with CAR as an insert. So, I have implemented the 
transfer of CAR structure to Lentivirus expression vector in two steps. First, 
The pDNAs were cleaved with appropriate restriction endonuclease (EcoR I, 
Spe I and Not I) (Fig 10 A). The cleavage reaction resulted in the formation of 
the linearized part of pDNA with the specific restriction endonuclease site at 
the end of this fragment, respectively. The pDNA of CAR on T vector was cut 
by restriction endonuclease (EcoR I, Spe I and Not I) result in 3 linearized 
strands (T vector, ‘scFv~Il2r𝛽 and Tgf𝛽r1+Cd3ζ). The ‘scFv~Il2r𝛽’ fragment 
has an EcoR I restriction endonuclease site at the end of 5’ and a Spe I restriction 
endonuclease site at the end of 3’. The ‘Tgf𝛽r1+Cd3ζ’ fragment has a Spe I 
restriction endonuclease site at the end of 5’ and a Not I restriction endonuclease 
site at the end of 3’. And, the ‘Tgf𝛽r1+Cd3ζ’ fragment was cloned into pLVX-
IRES-ZsGreen1 vector cleaved by restriction endonucleases (Spe I and Not I), 
and transformed. The transformation products were screened using a plate with 
antibiotics for selection. The colonies were identified by PCR at the estimated 
DNA size. Second, these ‘Tgf𝛽 r1+Cd3ζ ’ on Lentivirus expression vector 
fragment was cleaved by restriction endonuclease (EcoR I and Spe I). And, the 
cut ‘scFv~Il2r 𝛽  gene’ was cloned into this vector and transformed. The 
transformation products were screened and checked at the estimated DNA size. 
The cleavage reaction was conducted to determine the DNA size in the 
lentiviral expression vector and the size was identified (Fig 10 B). Taken 






Figure 10. Generation of CAR on Lentiviral expression vector. 
A) Separation of Spe I, Not I and EcoR I digested pDNA. Lane 1 represents the 
pDNA including CAR separated three strands (T vector, scFv+Cd28+Il2r𝛽 
gene and Tgf𝛽r1+Cd3ζ gene from the top side). Lane 2 represent the linearized 
lentiviral expression vector. The bands with cut CAR gene were extracted and 
purified. B) Separation of EcoR I and Not I digested pDNA of a lentiviral 




















Table 10. The unique oligonucleotide sequences.  






















































Transfection and Transduction of CARs. 
This CAR was transfected into HEK293FT cells by lipofection. The expression 
vector and packaging vectors were used to produce a lentiviral vector in 
HEK293FT cells. Harvested lentivirus has been tested in EL4 and HEK293FT 
cells, and the expression of ZsGreen fluorescence could be confirmed (Fig 13 















Figure 13. Transduction of CAR to cell line. 
The expression of CAR was confirmed by ZsGreen1 fluorescence in pLVX-
IRES-ZsGreen1 vector. The transduction of lentivirus with CAR was checked 
in HEK293FT cells (A) and EL4 cells (B). The virus supernatants were added 













Production of a cell line expressing mouse CD40L. 
I aimed to generate specific cell line expressing CD40L as antigen for CAR. 
DNA for CD40L was obtained from mouse CD4+ cell. I generated CD40LF and 
CD40LR primer, which contained the part of 5’ end of the CD40L gene, and 
the 3’ end of the CD40L gene, respectively (Table 11). And, the primer sequence 
with specific restriction endonuclease site (F: Bgl II, R: EcoR I) is incorporated 
into the PCR product during amplification (Fig 14 A). This PCR product was 
extracted and cloned to the T vector. The transformation products were screened 
using a plate with antibiotics for selection. The colonies were confirmed by 
PCR at the expected DNA size. The pDNA can be cleaved with appropriate 
restriction endonuclease (Bgl II and EcoR I) (Fig 14 B). The cleavage reaction 
results in the production of the linearized strand of pmCherry-C1 vector and the 
Cd40l gene as insertions with the specific restriction endonuclease site at the 
end of pDNA, respectively. And this Cd40l gene to be cloned into the 
pmCherry-C1 vector by T4 ligase, and transformed. The transformation product 
was screened using a plate with antibiotics for selection. The colonies were 









Figure 14. Generation of a pmCherry-C1 vector expressing CD40L. 
A) A PCR fragment of 783 bp from mouse CD40L gene. The PCR was 
implemented with CD40LF/CD40LR primer sets and cDNA of mouse CD4+ T 
cell as a template. B) Separation of the Bgl II and EcoR I digested pDNA. Lane 
1 represents the linearized pmCherry-C1 vector. Lane 2 represents the separated 
pDNA of T vector including CD40L gene. The fragment estimated size 4722 
















CD40LF AGATCT ATGATAGA AACATAC 
CD40LR GAATTC TCAGA GTTTGAGTAA G 
 
Table 11. The oligonucleotide sequences for the acquisition of the CD40L 
gene. 
The PCR product was amplificated with specific restriction enzyme site using 





















This vector expressing CD40L were transfected into HEK293FT cells by 
lipofection. And the expression of mCherry fluorescence could be confirmed 
by FACS and fluorescence microscope (Fig15 A and B). A small amount of 
vector pDNA with CD40L was transfected. The mCherry fluorescence and 


















Figure 15. Transfection of a vector expressing CD40L gene. 
A) The pmCherry-C1 vector with CD40L was transfected to HEK293FT cell in 
different quantity (0ng, 100ng from the top side). Representative plot of 
mCherry and CD40L expression of transfected HEK293FT cells. B) Expression 
















Activation of EL4 cell with CAR  
I confirmed the expression of CD40L gene in HEK293FT Cell. So, I checked 
the activation of EL4 cell including CAR, using HEK293FT cell expressing 
CD40L. The response of transduced EL4 cell to the CD40L as antigen was 
examined by CD69 expression level. The anti-CD3/CD28 mAb molecule 
promoted the expression of CD69 in EL4 cells (Fig 16 B). The EL4 cells co-
cultured with HEK293FT cells were also expressed the CD69 (Fig 16 C). And, 
Transduced EL4 cells co-cultured with transfected HEK293FT cells were 
expressed CD69 (Fig 16 D). But the expression level was higher in transfected 







Figure 16. Co-culture effect of EL4 cell expressing CAR on the response of 
HEK293FT cell expressing CD40L. 
The fluorescence expression level of EL4 cell (A). Transduced EL4 cell co-
culture effect in (B) anti-CD3/CD28 mAb, (C) HEK293FT cells, and (D) 










I describe a unique, useful strategy to generate CAR. This CAR has CD40L 
specific scFv, an extracellular spacer comprised of mouse CD28 hinge, CD28 
transmembrane domain, CD28 costimulatory domain, the intracellular domain 
of IL-2Rβ and TGF-βR1, and an intracellular CD3ζ signaling region. This 
new CAR design is unusual in that it has the identical costimulatory and CD3ζ 
signaling regions but also include the intracellular domain of IL-2Rβ and TGF-
βR1 compared to conventional CARs. The inclusion of the intracellular domain 
of IL2-Rβ and TGF-βR1 enabled conversion of naïve T cells to iTreg with 
CARs in an antigen-dependent manner. In response to an antigen, I expect this 
CAR construct converts the naïve T cell to Treg, and then this converted t cell 
could suppression function and block the effector T cell by binding these cell 
directly to CD40L. 
 Here, I generated a CAR construct using cloning and PCR techniques. I 
acquired each gene by PCR using taq and pfu polymerase for preventing 
mutation. At this time, considering the site to be ligated, a restriction 
endonuclease site was inserted in the primer. The restriction site also 
constituted a condition that did not truncate each gene. The genes from PCR 
were extracted, purified, and transformed into T vector. The genes obtained in 
the form of pDNA were cloned again for ligation, or extended by OE-PCR 
technique. And finally, the CAR construct was designated. 
 The CAR was transfected into HEK293FT cells by lipofection. And the 
harvested virus was transduced in HEK293FT cell for test and EL4 cell. The 
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expression of ZsGreen1 fluorescence was detected by FACS. The percentage 
of the transduced cell with CAR construct was higher in HEK293FT cell than 
EL4 cell. But, I demonstrated that these CARs could be efficiently delivered 
into the mouse T cell line by lentiviral transduction. 
 Moreover, I generated the HEK293FT cell expressing CD40L as the antigen 
of CAR. The CD40L gene was derived from mouse CD4+ T cell. And, this gene 
was cloned into a pmCherry-C1 vector. And I confirmed the expression of 
mCherry fluorescence by FACS and fluorescence microscopy. The expression 
level was 40% in the amount of 100 ng pDNA with CD40L gene. I not shown 
here, I confirmed that the expression level was increased at a larger amount of 
pDNA. Furthermore, I checked the activation of EL4 cells including CAR 
construct, using HEK293FT cells expressing CD40L. The response of 
transduced EL4 cell to the CD40L as the antigen of the CAR was checked by 
CD69 expression level. And, the CD69 expression level was higher in 
transfected HEK293FT cells co-culture set compared in not transfected 
HEK293FT cells. 
 The CARs have principally been used to generate cancer-specific effector T 
cells. And this CAR-T therapy had a positive effect and resulted in the 
development of new cell therapy (27). Furthermore, CAR-T therapy was 
evolved in Treg. Many studies of CAR-Treg have been performed, and its 
efficacy has been proved. The prevention efficacy of CAR-Treg with MHC 
specificity was demonstrated in allograft rejection. Also, The efficacy of human 
CAR Tregs was demonstrated in the prevention of xeno-GVHD (28). These 
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CAR-Treg designs suggest a successive useful possibility to induce graft-
specific tolerance as a new therapy.  
In the transplantation model, the finding of the new antigen of the donor offers 
an essential role. Also, the CAR design has higher specificity result in off-target 
effect without cross-reactivity to avoid an unexpected effect (29). In current 
trails, the Tregs for adoptive therapy was used to treat patients (30). But there 
is a limit to long expansion time, which is critical severely ill patients. However, 
the A2-CAR Tregs have engineered with ‘off-the-shelf’ strategy with 
significant functional effect and short expansion time results in powerful 
expected function for treatment (31).  
I generated CAR-T cells which can convert into CAR-iTreg upon antigen 
simulation, and I accordingly expected this CAR-T cells to be a therapeutic tool 
to effectively regulate the immune response in transplantation or autoimmune 
disease model. This CAR with CD40L specificity might offer a novel strategy 
to achieve tolerance after organ transplantation (32). And also, based on CAR 
construct explained here, the CAR specific for different new antigens might 
provide the significant potential of the CAR technology. This work I described 
here is the first proof-of-concept for the generation of CAR-iTreg with potential 
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서론: 조절 T 세포는 흉선에서 유래된 억제 능력을 가진 세포로 자
가항원에 대한 면역관용을 유지하는데 중요한 역할을 한다. 본 연구
에서는 키메라 항원 수용체를 사용하여 CD40L 자극을 받으면 미감
작 T 세포를 조절 T 세포로 분화시키는 새로운 기술을 개발하였다. 
키메라 항원 수용체는 세포 외 영역은 주로 항체에서 유래되고, 세
포 내 신호전달 영역은 T 세포의 신호전달 부분에서 유래된 합성 
단백질이다. 키메라 항원 수용체의 세포내 영역에 TGF- β  수용체의 
세포질 부분과 IL-2Rβ의 신호전달 영역 부분을 포함시켰다. 그 결과, 
2 세대 키메라 항원 수용체를 기반으로 하여, MR1 단일 항체의 scFv
와 CD28, IL-2Rβ, TGF-βR1, CD3ζ의 부분을 클로닝을 통해 합성하였
고 CD40L 의 특이성을 가지는 키메라 항원 수용체를 제작하였다.  
 
방법: 마우스 CD4+ T 세포는 MACS 시스템을 이용하여 분리하였다. 
그리고 이 유전자들은 키메라 항원 수용체를 구성하는데 사용되었
다. 각 유전자들은 중합효소연쇄반응에 의해 특정 올리고뉴클레오티
드를 사용하여 증폭하고 연결시켜 재조합 유전자를 합성하였다. 합
성된 키메라 항원 수용체는 렌티바이러스 벡터에 삽입되었다. 이 벡
터와 운반벡터들을 사용하여, 키메라 항원 수용체를 암호화하는 
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DNA 를 포함하는 재조합 렌티바이러스를 만들었으며, 수확된 바이
러스는 EL4 세포에 형질전환에 사용되었다.  
 
결과: 키메라 항원 수용체 구조는 마우스 cDNA 로부터 얻은 후 합
성하였다. 완성된 키메라 항원 수용체는 렌티바이러스 벡터에 삽입
되었다. 그리고 키메라 항원수용체의 발현은 pLVX-IRES-ZsGreen1 
벡터에 있는 ZsGreen 형광으로 확인하였다. 또한 키메라 항원 수용
체에 특이적으로 결합하는 CD40L 를 발현하는 세포주를 만들었고 
mCherry 형광을 이용하여 발현을 확인하였다. 키메라 항원수용체를 
발현하는 EL4 세포와 CD40L 를 발현하는 HEK293FT 세포를 함께 
배양하고, 키메라 항원수용체를 발현하는 EL4 세포의 활성여부를 
CD69 의 발현을 통해 확인하였다.  
 
결론: 본 연구에서는 새로운 키메라 항원 수용체를 발현시킬 수 있
는 재조합 유전자를 합성하였는데, 기존의 수용체와 비교하였을 때, 
IL-2Rβ와 TGF-βR1 의 세포내 영역을 포함한다는 점에서 특별하다. 
IL-2Rβ와 TGF-βR1 의 세포내 영역은 항원 의존적으로 미감작 T 세
포가 조절 T 세포로 전환되는 것을 가능하게 한다. 이러한 키메라 
항원수용체 구조가 이식 모델과 자가면역질환 모델에서 사용된다면, 
유의미한 면역억제능력을 유도할 수 있을 것으로 기대한다. CD40L 
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특이성을 가지는 키메라 항원 수용체는 장기 이식후에 면역관용을 




주요어 : 조절 T 세포, 키메라 항원 수용체, 중합효소 연쇄반응, 클로
닝, 형질 전환, 형질도입 
학  번 : 2017-22413  
 
 
 
 
